VanEck Biotech ETF (NASDAQ:BBH) Short Interest Up 112.5% in January

VanEck Biotech ETF (NASDAQ:BBH) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 1,700 shares, a growth of 112.5% from the December 31st total of 800 shares. Based on an average daily trading volume, of 9,000 shares, the short-interest ratio is currently 0.2 days.

VanEck Biotech ETF Stock Performance

Shares of VanEck Biotech ETF stock opened at $164.62 on Wednesday. The business has a 50-day moving average price of $161.83 and a 200 day moving average price of $171.11. VanEck Biotech ETF has a twelve month low of $151.35 and a twelve month high of $183.64.

VanEck Biotech ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Investors Weigh In On VanEck Biotech ETF

Institutional investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC acquired a new position in VanEck Biotech ETF during the third quarter worth $44,000. FSA Wealth Management LLC purchased a new stake in shares of VanEck Biotech ETF during the third quarter worth about $54,000. Coastline Trust Co acquired a new position in shares of VanEck Biotech ETF during the 3rd quarter worth about $59,000. Wilmington Savings Fund Society FSB purchased a new position in VanEck Biotech ETF in the 3rd quarter valued at about $166,000. Finally, Tyler Stone Wealth Management boosted its holdings in VanEck Biotech ETF by 79.5% in the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock worth $261,000 after buying an additional 652 shares during the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.